Skip to main content

Table 1 Baseline characteristics, treatments, and outcomes of patients with COVID-19 with UC-MSC therapy

From: Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia

  Total (n = 31)
Demographics and clinical characteristics
 Age, median (IQR), years 70 (61–71)
 Sex, male 25 (80.6%)
 BMI, mean ± SD, kg/m2 24.5 ± 2.9
Symptoms at admission
 Fever 24 (77.4%)
 Cough 25 (80.6%)
 Dyspnea 17 (54.8%)
 Chest congestion 14 (45.2%)
 Fatigue 12 (38.7%)
Comorbidities
 Hypertension 13 (41.9%)
 Chronic obstructive pulmonary disease 6 (19.4%)
 Coronary artery disease 5 (16.1%)
 Diabetes 5 (16.1%)
Chest computed tomographic findings
 Bilateral pneumonia 31 (100%)
 Multiple mottling/ground-glass opacity 26 (83.9%)
Main complications
 Respiratory failure 10 (32.3%)
 Acute respiratory distress syndrome 8 (25.8%)
 Cardiac injury 12 (38.7%)
Disease severity status
 Severe 23 (74.2%)
 Critical 8 (25.8%)
 Days between onset of symptoms and hospital admission, mean ± SD, days 37.2 ± 17.6
 Days between onset of symptoms and UC-MSC therapy, mean ± SD, days 50.7 ± 12.6
 Days between hospital admission and UC-MSC therapy, median (IQR), days 10.0 (6.0–22.0)
 Intensive care unit admission 16 (51.6%)
Treatments
 Oxygen 31 (100%)
 Oxygen inhalation 19 (61.3%)
 Noninvasive mechanical ventilation 4 (12.9%)
 Invasive mechanical ventilation 8 (25.8%)
 Antivirals 26 (83.9%)
 Arbidol 20 (64.5%)
 Interferon alfa-2b 9 (29.0%)
 Oseltamivir 3 (9.7%)
 Chloroquine 3 (9.7%)
 Antibiotics 23 (74.2%)
 Methylprednisolone 6 (19.4%)
UC-MSC therapy
 UC-MSC volume, median (IQR), mL 200 (100–300)
 Single infusion of UC-MSCs 11 (35.5%)
 Two infusions of UC-MSCs 9 (29.0%)
 Three infusions of UC-MSCs 11 (35.5%)
 Intravenous immunoglobulin therapy 8 (25.8%)
 Intravenous albumin therapy 8 (25.8%)
Outcomes
 SARS-CoV-2 clearance 30 (96.8%)
 Discharged 27 (87.1%)
 Death 4 (12.9%)
  1. UC-MSCs umbilical cord mesenchymal stem cells, IQR interquartile range, SD standard deviation, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2